Carbamazepine (All indications)

Neonatal intracranial hemorrhage

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9606
R34055		 Burja (Carbamazepine) (Controls unexposed, disease free), 2006 Intracranial hemorrhage during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, disease free excluded Adjustment: No 10.99 [2.67;45.25] C
excluded (control group) 		4/19   5/211 9 19
ref
S9607
R34060		 Burja (Carbamazepine) (Controls unexposed, sick), 2006 Intracranial hemorrhage during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No 4.00 [0.66;24.37] C 4/19   2/32 6 19
ref
S9612
R34106		 D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 Periventricular haemorrhage (germinal layer) throughout pregnancy prospective cohort unexposed, disease free excluded Adjustment: No Matched 24.60 [0.40;1512.72] C
excluded (control group) 		0/3   0/62 0 3
ref
S9613
R34135		 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 Periventricular haemorrhage (germinal layer) throughout pregnancy prospective cohort unexposed, sick Adjustment: No 3.00 [0.05;194.76] C 0/3   0/8 0 3
ref
Total 2 studies 3.82 [0.73;20.07] 6 22
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Burja (Carbamazepine) (Controls unexposed, sick), 2006Burja, 2006 1 4.00[0.66; 24.37]61984%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA D'Souza (Carbamazepine) (Controls unexposed, sick), 1991D'Souza, 1991 2 3.00[0.05; 194.76]0316%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 3.82[0.73; 20.07]6220.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.82[0.73; 20.07]6220%NABurja (Carbamazepine) (Controls unexposed, sick), 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 3.82[0.73; 20.07]6220%NABurja (Carbamazepine) (Controls unexposed, sick), 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 2 Tags Adjustment   - No  - No 3.82[0.73; 20.07]6220%NABurja (Carbamazepine) (Controls unexposed, sick), 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 2 All studiesAll studies 3.82[0.73; 20.07]6220%NABurja (Carbamazepine) (Controls unexposed, sick), 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9612, 9606

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale11.96[3.14; 45.62]9220%NABurja (Carbamazepine) (Controls unexposed, disease free), 2006 D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 2 unexposed, sick controlsunexposed, sick controls 3.82[0.73; 20.07]6220%NABurja (Carbamazepine) (Controls unexposed, sick), 2006 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 20.510.01.0